[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"primary-liver-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:primary-liver-cancer":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,11,0,[8,70,98,128,148,176,205,234,258,281,304],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":33,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":69},"100604152","phase-2-y-90-treatment-response-using-transarterial-radioembolization-100604152",false,"NCT07145801","Y-90 Treatment Response Using Transarterial Radioembolization","Contrast-Enhanced Ultrasound Evaluation of Radioembolization Treatment Response","TARE","Inclusion Criteria:\n\n* Scheduled for TARE therapy of a treatment naïve HCC visible on ultrasound.\n* Be at least 18 years of age.\n* Be medically stable.\n* If a female of child-bearing age, must have a negative pregnancy test.\n* Have signed Informed Consent to participate in the study.\n\nExclusion Criteria:\n\n* Patients who are medically unstable, patients who are seriously or terminally ill, and patients whose clinical course is unpredictable.\n* Patients with known sensitivities to the components of Lumason.\n* Patients with known sensitivities to the components of Sonazoid.","ALL","18 Years",{"count":20,"type":21},30,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","This prospective clinical study will examine the ability of contrast-enhanced ultrasound (CEUS) to assess the treatment response of hepatocellular carcinoma (HCC) to transarterial radioembolization (TARE). HCC is the third leading cause of cancer mortality worldwide and the single fastest growing cause of cancer mortality in the United States. TARE is recommended for 15-25% of HCC patients. Treatment response is generally evaluated using contrast-enhanced CT or MRI 1-2 months and 4-6 months post-TARE. Although TARE is an effective therapy, assessment of treatment response using CT\u002FMRI is challenging because CT\u002FMRI frequently diagnoses tumor response as equivocal or non-progressing for up to 6 months post-TARE based on LI-RADS criteria. This delay in diagnosing tumor viability subsequently delays needed retreatment and can even serve as a barrier to transplantation. Our prior work in HCC locoregional therapy has shown CEUS provides improved sensitivity in detecting viable tumor following transarterial chemoembolization relative to traditional CT\u002FMRI. Therefore, the investigators propose to evaluate both qualitative and quantitative CEUS as a tool for evaluating HCC post-TARE at similar time points of clinically recommended cross-sectional imaging, while also investigating the role of Kupffer phase imaging.\n\nThe investigators plan to enroll a total of 30 patients scheduled for TARE of a treatment naïve HCC over an 18-month period, allowing for a minimum of 6 months follow up. Patients will undergo a CEUS examination within two weeks of their first two clinically indicated CT\u002FMRI exams (obtained at Jefferson 1-2 months and 4-6 months post TARE). In patients retreated prior to their 4-6 month MRI, CEUS may also be performed in the absence of the MRI at this time point but prior to retreatment. Patients will be recruited across six major hospitals within the Jefferson Health Enterprise. Those eligible for participation will be identified by project co-investigators and contacted by the study coordinator to discuss participation and to explain the study. The patient will be given time to consider the risks and benefits of the study and ask questions about participation. If agreeable, the patient will then arrange with the project coordinator to come to Jefferson's center city campus to sign consent and take part in the research study.",[27,28,29,30,31,32],"HCC","Hepatocellular Carcinoma","Liver Cancer","Hepatic Neoplasm","Primary Liver Cancer","Liver Neoplasm",[34,15,35,36,37,38,27,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56],"transarterial radioembolization","CEUS","contrast-enhanced ultrasound","hepatocellular","carcinoma","hepatocellular carcinoma (HCC)","liver cancer","liver tumors","liver lesions","microbubbles","liver parenchyma","liver imaging","HCC locoregional therapy","Ultrasound","Kupffer","Yttrium-90","tumor viability","time intensity curves","parametric maps","microbubble destruction","bolus contrast injection","CEUS biomarker","Y90 TARE","RECRUITING","2026-06-08",{"date":60,"type":61},"2026-06-10","ACTUAL",{"date":63,"type":61},"2025-09-11",{"date":65,"type":21},"2027-06-30",{"name":67,"class":68},"Thomas Jefferson University","OTHER",1,{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":74,"acronym":4,"eligibilityCriteria":75,"healthyVolunteers":11,"sex":17,"minAge":76,"maxAge":4,"enrollmentInfo":77,"targetDuration":4,"studyType":79,"phases":4,"briefSummary":80,"conditions":81,"keywords":86,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":20},"100553466","real-world-evaluation-of-the-histosonics-edison-system-for-treatment-of-liver-tumors-across-multidisciplinary-users-boombox-master-study-100553466","NCT06486454","Real-world Evaluation of the HistoSonics Edison System for Treatment of Liver Tumors Across Multidisciplinary Users (BOOMBOX: Master Study)","Inclusion Criteria:\n\n1. Subject is ≥22 years of age\n2. Subject has signed the Ethics Committee (EC), or Institutional Review Board (IRB) approved study Informed Consent Form (ICF) prior to any study related tests\u002Fprocedures and is willing to comply with study procedures and required follow-up assessments\n3. Subject's liver tumor(s) can be partially or completely treated with histotripsy\n\nExclusion Criteria:\n\n1. Subject is pregnant or planning to become pregnant or nursing (lactating) during the study period\n2. Subject is enrolled in an interventional HistoSonics-sponsored trial\n3. Subject has a concurrent condition that, in the investigator's opinion, could jeopardize the safety of the subject or compliance with the protocol","22 Years",{"count":78,"type":21},5000,"OBSERVATIONAL","The goal of this observational study is to collect information on the use of the HistoSonics Edison System for the treatment of liver tumors. The main aim is to understand how different patient characteristics and procedural characteristics may affect histotripsy success at 36 hours post-histotripsy procedure. Sub-studies to the BOOMBOX: Master Study will investigate specific populations and\u002For clinical questions with more stringent enrollment criteria, standardized testing criteria, and\u002For follow-up schedule. Any participant enrolled in the BOOMBOX: Master Study that also qualifies for a sub-study may enroll in the sub-study in parallel; sub-studies will be described in separate sub-study protocols. The BOOMBOX: Master Study will collect information about participants before, during, and after the histotripsy treatment procedure. All participants will be followed per standard clinical follow-up based on each site's clinical practice for up to 5 years after the initial histotripsy procedure or until completion of their follow-up in a sub-study, whichever is longer.",[82,31,83,84,85],"Liver Neoplasms","Secondary Liver Cancer","Tumor Liver","Benign Liver Tumor",[87],"histotripsy","2026-06-01",{"date":90,"type":61},"2026-06-03",{"date":92,"type":61},"2024-10-14",{"date":94,"type":21},"2031-11",{"name":96,"class":97},"HistoSonics, Inc.","INDUSTRY",{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":102,"acronym":103,"eligibilityCriteria":104,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":105,"targetDuration":4,"studyType":79,"phases":4,"briefSummary":107,"conditions":108,"keywords":114,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":127},"100542403","an-exosome-based-liquid-biopsy-for-the-differential-diagnosis-of-primary-liver-cancer-100542403","NCT06342414","An Exosome-Based Liquid Biopsy for the Differential Diagnosis of Primary Liver Cancer","ELUCIDATE","Inclusion Criteria:\n\n* A histologically confirmed diagnosis of hepatocellular carcinoma\n* A histologically confirmed diagnosis of intrahepatic cholangiocarcinoma\n* Received standard diagnostic and staging procedures as per local guidelines\n* Availability of at least one blood-derived sample, drawn before receiving any curative-intent treatment\n\nExclusion Criteria:\n\n* Lack of or inability to provide informed consent\n* Synchronous hepatocellular carcinoma and intrahepatic cholangiocarcinoma\n* Primary liver cancer other than hepatocellular carcinoma or intrahepatic cholangiocarcinoma\n* Secondary liver cancer",{"count":106,"type":21},400,"It is sometimes difficult to precisely understand whether a primary liver cancer is a hepatocellular carcinoma or a cholangiocarcinoma. The researchers will develop and validate a liquid biopsy, based on exosomal content analysis and powered by machine learning, to help clinicians differentiate these two cancers before surgery.",[28,109,110,31,111,112,113],"Intrahepatic Cholangiocarcinoma","Cholangiocarcinoma","Primary Liver Carcinoma","Hepatic Cancer","Hepatic Carcinoma",[115,116,117],"Exosome","micro RNA","Differential Diagnosis","2026-04-01",{"date":120,"type":61},"2026-04-03",{"date":122,"type":61},"2024-03-15",{"date":124,"type":21},"2026-06-18",{"name":126,"class":68},"City of Hope Medical Center",5,{"id":129,"slug":130,"hasResults":11,"nctId":131,"briefTitle":132,"officialTitle":133,"acronym":4,"eligibilityCriteria":134,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":135,"targetDuration":4,"studyType":79,"phases":4,"briefSummary":137,"conditions":138,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":139,"lastUpdatePostDateStruct":140,"startDateStruct":142,"completionDateStruct":144,"leadSponsor":146,"locationsCount":69},"100628819","cfdna-methylation-for-liver-cancer-recurrence-detection-100628819","NCT07466602","cfDNA Methylation for Liver Cancer Recurrence Detection","Clinical Study on the Combined Detection of Plasma GNB4 and Riplet Gene Methylation for Monitoring Primary Liver Cancer Recurrence","Inclusion Criteria:\n\n* Primary liver cancer\n\nExclusion Criteria:\n\n* Concurrent other malignant tumors;\n* Ineligible for hepatectomy, liver transplantation, ablation, or TACE therapy;\n* Negative methylation status prior to treatment.",{"count":136,"type":21},500,"Through follow-up testing of patients with primary liver cancer who underwent hepatectomy, liver transplantation, ablation therapy, or transarterial chemoembolization (TACE), a blinded comparative trial was conducted at each monitoring site. This trial evaluated the combined methylation detection kit for GNB4 and Riplet genes (fluorescent PCR method) against the clinical reference standard (defined as the physician's comprehensive diagnosis based on clinical guidelines and other criteria). The study evaluated the clinical performance of the assay in diagnosing primary liver cancer recurrence and validated the clinical efficacy of methylation detection kits for monitoring recurrence after primary liver cancer treatment.",[31],"2026-03-19",{"date":141,"type":61},"2026-03-23",{"date":143,"type":61},"2025-09-02",{"date":145,"type":21},"2027-12-31",{"name":147,"class":97},"Wuhan Ammunition Life-tech Co., Ltd",{"id":149,"slug":150,"hasResults":11,"nctId":151,"briefTitle":152,"officialTitle":153,"acronym":4,"eligibilityCriteria":154,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":155,"enrollmentInfo":156,"targetDuration":4,"studyType":79,"phases":4,"briefSummary":158,"conditions":159,"keywords":162,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":167,"lastUpdatePostDateStruct":168,"startDateStruct":170,"completionDateStruct":172,"leadSponsor":174,"locationsCount":69},"100600726","an-exploratory-study-on-developing-an-integrated-approach-combining-multimodal-imaging-and-multi-omics-characterization-of-tumor-heterogeneity-for-precision-diagnosis-and-treatment-optimization-in-liver-cancer-100600726","NCT07101237","An Exploratory Study on Developing an Integrated Approach Combining Multimodal Imaging and Multi-omics Characterization of Tumor Heterogeneity for Precision Diagnosis and Treatment Optimization in Liver Cancer.","Integrative Multimodal Imaging and Multi-omics Profiling of HCC Heterogeneity: a Translational Exploratory Study Leveraging CEUS, Elastography, SMI, PAI, Multi-omics Analysis, and AI-driven Modeling to Advance Precision Diagnosis and Therapeutic Optimization","Inclusion Criteria:\n\n1. Age \\>18 and ≤70 years;\n2. Both sexes eligible;\n3. Diagnosed with primary HCC or ICC;\n4. Scheduled for surgical resection or conversion therapy;\n5. Pathologically confirmed HCC\u002FICC via surgery or biopsy;\n6. Posterior margin of the lesion ≤ 8 cm from the skin surface.\n\nExclusion Criteria:\n\n1. Pregnancy, lactation, or planned pregnancy during the study period;\n2. History of other malignancies;\n3. Cardiac, pulmonary, cerebral, or renal insufficiency;\n4. Lesion depth \\>8 cm from the skin surface on ultrasound;\n5. Massive ascites;\n6. Poor compliance (e.g., inability to hold breath during examination);\n7. Allergy to ultrasound contrast agents.","70 Years",{"count":157,"type":21},308,"Primary liver cancer, mainly including hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC), represents the third leading cause of cancer-related mortality. Enhancing the precision of liver cancer diagnosis and providing early therapeutic efficacy and prognostic evaluation during clinical decision-making hold significant clinical importance. Ultrasound is the preferred imaging modality for liver cancer screening. Contrast-enhanced ultrasound (CEUS) can dynamically visualize the microvascular perfusion of liver cancer lesions. Liver elastography has become a commonly used clinical assessment tool for cirrhosis. Photoacoustic imaging (PAI), an emerging non-invasive functional imaging technique, enables visualization of specific molecules through their spectroscopic characteristics at designated wavelengths.\n\nThe objectives of this study include: (1) Conducting an observational investigation combining CEUS, elastography, and superb microvascular imaging (SMI) to collect imaging data; (2) Preserving tumor specimens from participants to investigate heterogeneous protein characteristics of primary liver cancer organoids using PAI; (3) Analyzing peripheral venous blood samples to study transcriptomic profiles. Artificial intelligence (AI) technology will be employed to establish models integrating ultrasound radiomics with tumor multi-omics characteristics, aiming to provide novel strategies for precision diagnosis and treatment of liver cancer.\n\nKey questions：(1) How to develop a multimodal imaging model combining CEUS, elastography, and SMI for predicting differentiation of liver cancer, microvascular invasion (MVI) and prognosis; (2) Whether PAI can identify heterogeneous proteins in liver cancer organoids through specific spectral recognition; (3) Whether AI can integrate multi-dimensional data to establish models based on ultrasound radiomics and multi-omics features.",[160,161,31],"Hepatocellular Carcinoma (HCC)","Intrahepatic Cholangiocarcinoma (ICC)",[40,27,163,164,165,166],"contrast-enhanced ultrasound (CEUS)","elastography","superb microvascular imaging (SMI)","photoacoustic imaging (PAI)","2025-07-31",{"date":169,"type":61},"2025-08-03",{"date":171,"type":61},"2024-08-01",{"date":173,"type":21},"2030-12-31",{"name":175,"class":68},"Peking Union Medical College Hospital",{"id":177,"slug":178,"hasResults":11,"nctId":179,"briefTitle":180,"officialTitle":181,"acronym":4,"eligibilityCriteria":182,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":183,"targetDuration":4,"studyType":22,"phases":185,"briefSummary":187,"conditions":188,"keywords":189,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":195,"lastUpdatePostDateStruct":196,"startDateStruct":198,"completionDateStruct":200,"leadSponsor":202,"locationsCount":204},"100586382","the-dragon-plc-trial-dragon-plc-100586382","NCT06914648","The Dragon PLC Trial (DRAGON-PLC)","The DRAGON PLC Trial - An International Multicenter Randomized Controlled Trial to Compare Combined Portal and Hepatic Vein Embolization (PVE\u002FHVE) With PVE Alone in Primary Liver Cancers.","Inclusion Criteria:\n\n* PLC diagnosis, specifically iCCC, pCCC, and HCC;\n* Requiring PVE due to an FLR volume is \\\u003C30% in normally functioning livers, \\\u003C40% in livers with potentially impaired function e.g. resulting from prior systemic therapy induction or bile duct colonization \u002F transpapillary biliary drainage, or \\\u003C50% in livers with severely impaired function resulting from liver cirrhosis (max. Child Pugh A5) OR function on hepatobiliary scintigraphy (HEBIS) is \\\u003C 2.7 %\u002Fmin\u002Fm2;\n* Age ≥ 18 years;\n* Able to understand the trial and provide informed consent.\n\nExclusion Criteria:\n\n* Liver cirrhosis with a Child-Pugh score of B or C;\n* Presence of portal hypertension;\n* Presence of cholangitis;\n* Pregnant women;\n* Premenopausal females not able\u002Fwilling to commit to contraception (specifically long-acting reversible contraception or hormonal contraception);\n* Patients unresectable due to prohibitive comorbidities (decision made by local multidisciplinary team);\n* Patients with hepatic malignancies other than iCCC, pCCC or HCC;\n* PVE\u002FHVE anatomically not feasible;\n* Any patient with non-resectable or non-ablatable extrahepatic metastatic disease.\n* Unable to understand the study information, study instructions and give informed consent",{"count":184,"type":21},358,[186],"NA","The goal of the DRAGON PLC clinical trial is to determine whether portal vein embolization (PVE) combined with hepatic vein embolization (HVE) improves resectability and overall survival in patients with initially unresectable primary liver cancer compared to standard PVE alone. This trial specifically focuses on patients with hepatocellular carcinoma and cholangiocarcinoma.\n\nThe main questions this trial aims to answer are whether combined PVE and HVE increases the proportion of patients who become resectable within 3 weeks and improves 5-year overall survival compared to PVE alone by enhancing liver hypertrophy.\n\nParticipants will:\n\n* Undergo either standard PVE or combined PVE and HVE.\n* Have regular imaging to assess liver resectability.\n* Be monitored for survival outcomes up to 5 years after intervention.",[31,160,110],[190,191,192,193,194],"Primary liver cancer","Future Liver Remnant","Liver regeneration","Portal Vein Embolization (PVE)","Hepatic Vein Embolization (HVE)","2025-05-12",{"date":197,"type":61},"2025-05-15",{"date":199,"type":61},"2025-04-01",{"date":201,"type":21},"2032-11-15",{"name":203,"class":68},"Maastricht University",55,{"id":206,"slug":207,"hasResults":11,"nctId":208,"briefTitle":209,"officialTitle":210,"acronym":4,"eligibilityCriteria":211,"healthyVolunteers":11,"sex":17,"minAge":212,"maxAge":155,"enrollmentInfo":213,"targetDuration":4,"studyType":22,"phases":215,"briefSummary":216,"conditions":217,"keywords":221,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":226,"lastUpdatePostDateStruct":227,"startDateStruct":228,"completionDateStruct":230,"leadSponsor":232,"locationsCount":69},"100585642","stroke-volume-variation-versus-central-venous-pressure-guidance-for-reducing-perioperative-blood-loss-during-open-liver-resection-100585642","NCT06905015","Stroke Volume Variation Versus Central Venous Pressure Guidance for Reducing Perioperative Blood Loss During Open Liver Resection","Comparison the Effectiveness of Stroke Volume Variation Versus Central Venous Pressure Guidance for Reducing Perioperative Blood Loss During Open Liver Resection: A Prospective, Double-Blinded, Noninferiority, Randomized Controlled Study","Inclusion Criteria:\n\n* All genders, age 18 to 70 years old\n* American Society of Anesthesiologists (ASA) physical status classification of I-III\n* The patients who scheduled in elective open liver resection and diagnosed Hepatocellular Carcinoma, Cholangiocarcinoma, Liver metastasis, and Benign malignant tumor.\n\nExclusion Criteria:\n\n* Pregnancy\n* Active cardiac conditions (unstable coronary syndromes, decompensated heart failure, significant arrhythmias, severe valvular disease, active coronary artery disease within 6 months prior surgery)\n* History of significant cerebrovascular disease (Patients with clinically significant stroke\u002FCVA within 6 months prior surgery, severe carotid stenosis)\n* Renal dysfunction (GFR \\\u003C 60 ml\u002Fmin\u002F1.73 m²)\n* Abnormal coagulation parameters (INR \\>1.5 not on warfarin and\u002For platelet count \\\u003C100,000)\n* Preoperative autologous blood donation\n* Tumor size \\> 10 cm.\n* Previous liver resection\n\nWithdrawal criteria:\n\n* Unresectable tumor\n* Persistent intraoperative hypotension that cannot be corrected with vasopressors.\n* Cardiac arrest during operation\n* Low central venous pressure (CVP \\\u003C 5 mmHg) or high stroke volume variation (SVV \\>13%) cannot be achieved before and during liver parenchymal transection.","20 Years",{"count":214,"type":21},74,[186],"Liver resection is a major surgery that can be associated with significant intraoperative blood loss and blood transfusion. Among high-volume centers, median intraoperative blood loss ranges between 300-800 ml. Excessive blood loss is a strong independent predictor of worsened postoperative outcomes, increasing morbidity and mortality rates by 20%-35%. Additionally, perioperative allogeneic blood transfusions are associated with deleterious outcomes, including tumor recurrence and increased rates of complications and death.\n\nThe liver is a highly vascular organ with minimal vascular resistance, receiving up to 25% of cardiac output and pooling 20% of the splanchnic blood. Hepatic veins are a common source of venous hemorrhage. The pressure in the hepatic veins is directly correlated with the pressure in the vena cava and reducing cardiac preload results in decreased hepatic vein congestion. Therefore, low central venous pressure anesthesia (typically below 5 mmHg) can reduce the pressure gradient for retrograde venous bleeding, facilitate the outflow of blood from hepatic veins, and decrease blood volume and pressure in the liver. This anesthetic method is the standard technique to minimize blood loss during liver resection.\n\nCentral venous pressure was the static parameter used to indicate the right ventricular end-diastolic volume index (RVEDI) and was believed to be correlated with volume status. Despite this, central venous pressure did not reliably predict preload responsiveness due to the curvilinear shape of the ventricular pressure-volume curve, which indicates a poor relationship between ventricular filling pressure and volume. Additionally, the placement of a central venous catheter could lead to serious complications such as arterial cannulation, pneumothorax, and infection.\n\nArterial waveform analysis is dynamic hemodynamic monitoring based on the interaction between the heart and lungs in patients with mechanical ventilation. Stroke volume variation (SVV) is one aspect of arterial pressure waveform analysis and is a less invasive alternative technique for guiding preload status and fluid management in patients undergoing major abdominal surgery.\n\nIn liver resection, several anesthetic methods are used to achieve low central venous pressure (CVP \\\u003C 5 mmHg) during the liver parenchymal dissection phase. These methods include intraoperative volume restriction, administration of venodilators or vasodilators, the use of forced diuresis with furosemide, and the implementation of hypovolemic phlebotomy. As mentioned, central venous pressure is a static hemodynamic monitoring parameter and poorly correlates with volume status. Recently, stroke volume variation has been recognized as a good parameter to predict volume status and fluid responsiveness in patients undergoing liver resection. However, no previous publications have studied the efficacy of stroke volume variation monitoring compared with central venous pressure monitoring to reduce perioperative blood loss during open liver resection.\n\nThe study aimed to compare the efficacy of maintaining high stroke volume variation versus low central venous pressure in reducing perioperative blood loss during the liver transection phase in open liver resection.",[218,219,31,220,85],"Liver Tumor; Surgery","Primary Liver Tumor, Metastatic Liver","Liver Resection",[222,223,224,225],"Stroke volume variation","central venous pressure","open liver resection","blood loss","2025-03-25",{"date":199,"type":61},{"date":229,"type":61},"2024-11-25",{"date":231,"type":21},"2028-06-30",{"name":233,"class":68},"Warangkana Lapisatepun",{"id":235,"slug":236,"hasResults":11,"nctId":237,"briefTitle":238,"officialTitle":239,"acronym":4,"eligibilityCriteria":240,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":241,"enrollmentInfo":242,"targetDuration":4,"studyType":22,"phases":244,"briefSummary":245,"conditions":246,"keywords":247,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":249,"lastUpdatePostDateStruct":250,"startDateStruct":252,"completionDateStruct":254,"leadSponsor":256,"locationsCount":69},"100575004","phase-2-stereotactic-radiosurgery-versus-radiofrequency-ablation-for-primary-liver-cancer-100575004","NCT06766643","Stereotactic Radiosurgery Versus Radiofrequency Ablation for Primary Liver Cancer","A Prospective, Randomized, Controlled Phase II Clinical Trial of Stereotactic Radiosurgery Versus Radiofrequency Ablation in Primary Liver Cancer in a Special Site of Surgical Evaluation for Non-operable","Inclusion Criteria:\n\n1. Prior to implementing any trial-related procedures, written informed consent must be signed;\n2. Age ≥ 18 years and ≤ 75 years;\n3. Child-Pugh score ≤ 7;KPS score ≥ 70;\n4. The patient must be clearly diagnosed with hepatocellular carcinoma, usually confirmed through imaging (CT, MRI) or histological examination (biopsy);\n5. The tumor is located near major blood vessels\u002Fdiaphragm\u002Fliver capsule\u002Fliver hilum;\n6. Surgically assessed as inoperable hepatocellular carcinoma or recurrence of primary hepatocellular carcinoma within 2 years after radical treatment;\n7. According to the criteria for evaluating the efficacy of solid tumors, there should be at least one measurable lesion by imaging, with the lesion size not exceeding 5 cm; total number of lesions ≤ 3;\n8. No previous anti-tumor treatment;\n9. Normal liver (liver volume minus tumor volume) is sufficient;\n10. Normal major organ functions, including blood routine tests \\[absolute neutrophil count (ANC) ≥ 1.5 × 10\\^9, platelets ≥ 70 × 10\\^9, hemoglobin ≥ 80 g\u002FL\\], liver function tests \\[bilirubin \\\u003C 3.0 mg\u002FdL, international normalized ratio (INR) \\\u003C 1.7, albumin ≥ 2.8 g\u002FdL, aspartate transaminase (AST)\u002Falanine transaminase (ALT) \\\u003C 6\\], serum creatinine \\\u003C 1.5 times the upper limit of normal, or creatinine clearance ≥ 60 mL\u002Fmin;\n11. Stable respiration for more than 10 minutes;\n12. Expected survival time \\> 2 years.\n\nExclusion Criteria:\n\n1. Possible surgical intervention;\n2. Presence of other serious comorbidities, such as uncontrolled cardiovascular diseases, pulmonary diseases, or dysfunction of other organs, where the overall health status is poor and may result in treatment intolerance;\n3. Severe liver dysfunction exceeding the specific criteria defined in the trial;\n4. Other malignancies diagnosed within 5 years prior to the first treatment or at the time of diagnosis of hepatocellular carcinoma;\n5. Significant clinically meaningful bleeding symptoms or a clear bleeding tendency within 3 months prior to enrollment;\n6. Currently participating in an interventional clinical trial treatment, or having received other investigational drugs or used investigational devices within 4 weeks before the first treatment;\n7. Previous treatment with anti-target tumor therapies;\n8. History of upper abdominal radiotherapy;\n9. Uncontrolled active comorbidities;\n10. Not meeting the expected survival prognosis or unable to provide informed consent.","75 Years",{"count":243,"type":21},130,[24],"A phase II clinical trial of stereotactic radiosurgery versus radiofrequency ablation in the treatment of inoperable primary liver cancer in specific sites",[31],[248],"Primary liver cancer，Stereotactic body radiation therapy，Radiofrequency ablation therapy","2025-01-08",{"date":251,"type":61},"2025-01-09",{"date":253,"type":21},"2025-01",{"date":255,"type":21},"2026-12",{"name":257,"class":68},"Tianjin Medical University Cancer Institute and Hospital",{"id":259,"slug":260,"hasResults":11,"nctId":261,"briefTitle":262,"officialTitle":262,"acronym":4,"eligibilityCriteria":263,"healthyVolunteers":264,"sex":17,"minAge":18,"maxAge":241,"enrollmentInfo":265,"targetDuration":267,"studyType":79,"phases":4,"briefSummary":268,"conditions":269,"keywords":271,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":272,"lastUpdatePostDateStruct":273,"startDateStruct":275,"completionDateStruct":277,"leadSponsor":279,"locationsCount":69},"100549205","recurrent-liver-cancer-reconceptualization-and-reevaluation-100549205","NCT06430983","Recurrent Liver Cancer: Reconceptualization and Reevaluation","Inclusion Criteria:\n\n* Diagnosed with primary hepatocellular carcinoma or diagnosed with non-HCC\n* The patient or the patient's legal representative must be able to read, understand, and sign the informed consent form\n* Agree to provide blood samples and have good clinical compliance\n* Complete clinical basic information, including: the patient's unique traceability number (ID card number\u002Foutpatient number\u002Fhealth insurance card number), age, gender, imaging and\u002For pathological diagnosis results (for patients with primary liver disease), imaging examination confirmed heteromorphic liver cancer (for non-HCC patients)\n\nExclusion Criteria:\n\n* Pregnant women\n* Those who have received organ transplantation\n* Non-HCC patients diagnosed with other tumors\n* Patients with primary hepatocellular carcinoma complicated by other tumors\n* Those judged by the researcher as not meeting the inclusion criteria",true,{"count":266,"type":21},300,"2 Years","The goal of this observational study is to determine if a specific protein can serve as a novel indicator for the recurrence of liver cancer. The study will focus on recurrent liver cancer patients and compare participants to primary liver cancer patients as controls. The primary purpose is to assess whether the elevated levels of this protein can be used to monitor the recurrence of liver cancer.\n\nThe main questions it aims to answer are:\n\nIs the levels of the protein significantly elevated in recurrent liver cancer patients compared to primary liver cancer patients? Can the protein be used as a reliable biomarker for the early detection of liver cancer recurrence?\n\nResearchers will compare the protein levels in the following groups:\n\n50 recurrent liver cancer patients (training set) with abnormally high levels of the protein.\n\n250 recurrent liver cancer patients (validation set) to confirm the protein's elevation in a separate cohort.\n\nParticipants will be required to:\n\n* Provide blood samples for protein analysis.\n* Undergo regular follow-up visits for monitoring and data collection.\n* Allow access to their medical records for relevant clinical information.",[270,31],"Recurrent Liver Cancer",[270,31],"2024-12-09",{"date":274,"type":61},"2024-12-12",{"date":276,"type":61},"2024-07-01",{"date":278,"type":21},"2027-10-01",{"name":280,"class":68},"Nanjing Medical University",{"id":282,"slug":283,"hasResults":11,"nctId":284,"briefTitle":285,"officialTitle":286,"acronym":4,"eligibilityCriteria":287,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":241,"enrollmentInfo":288,"targetDuration":4,"studyType":22,"phases":290,"briefSummary":292,"conditions":293,"keywords":294,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":295,"lastUpdatePostDateStruct":296,"startDateStruct":298,"completionDateStruct":300,"leadSponsor":302,"locationsCount":69},"100424405","phase-1-clinical-study-of-vg161-in-subjects-with-advanced-primary-liver-cancer-100424405","NCT04806464","Clinical Study of VG161 in Subjects with Advanced Primary Liver Cancer","A Dose Ascending, Open Phase I Clinical Study to Evaluate the Safety, Tolerability , Pharmacokinetics Characteristics and Preliminary Effectiveness of VG161 in Subjects with Advanced Primary Liver Cancer","1. According to 'The Diagnostic and Therapeutic Criteria for Primary Liver Cancer' (NMPA, 2019 Edition), subject with advanced primary hepatocellular carcinoma, intrahepatic cholangiocarcinoma, combined hepatocellular which is refractory\u002Frelapsed after and\u002For intolerant of standard therapies or for which no standard therapy exists. For the second stage of Simon\\'s two-stage in part 2, only patients with advanced primary hepatocellular carcinoma will be enrolled.\n2. There are tumor lesions intrahepatic and \u002F or extrahepatic metastases that can be injected under B ultrasound and meet the volume requirements of the current dose group, and the longest diameter of injectable tumor lesion \\>1.5cm（or the shortest diameter of lymph node lesions）\n3. Eastern Cooperative Oncology Group (ECOG) scores 0 or 1.\n4. Life expectancy is at least 3 months.\n5. Required organ function:\n\n1\\) Hematology blood (no blood transfusion or colony stimulating factor treatment within 14 days): absolute neutrophil count (ANC)≥1.5×10\\^9L, platelets (PLT)≥75×10\\^9L, hemoglobin (Hb)≥85g\u002FL; 2) Liver function: Total Serum bilirubin (TBIL)≤1.5×ULN (the upper limit of the reference range), Alanine aminotransferase (ALT)≤5×ULN, aspartate aminotransferase (AST)≤5×ULN; 3)Child-Pugh A-B level; 4) Renal function: Serum creatinine≤1.5×ULN, and creatinine clearance≥45 ml\u002Fmin (calculated per Cockcroft-Gault formula); 5) Coagulation function: activated partial thromboplastin time (APTT)≤1.5×ULN, prothrombin time(PT) ≤1.5×ULN, international standardized ratio (INR)≤1.5×ULN.\n\n6\\. Subjects who are HBV-DNA negative; or HBV-DNA positive are required to receive treatment in accordance with the 'Guidelines for the prevention and treatment of chronic hepatitis B' (2019 Edition) or clinical practice.\n\n7.Subjects of childbearing potential (male and female) must agree to use a reliable contraceptive method (hormone or barrier method or abstinence) during the study and for at least 90 days following the last dose; females of childbearing potential must have a negative blood pregnancy test within 7 days of study enrollment.\n\n8.Signed written informed consent.\n\nExclusion Criteria:\n\n1. Subject in prior anti-tumor therapies such as chemotherapy, radiotherapy, biotherapy, endocrinotherapy, targeted therapy, immunotherapy within 4 weeks of study treatment initiation. Oral fluorouracil analogues and small molecule targeted drugs were 2 weeks prior to the first dose of study drug or within 5 half-lives of the drug (whichever was longer).\n2. Transcatheter arterial chemoembolization(TACE) within 4 weeks of study treatment initiation\n3. Participation in clinical trials of any other investigational agents within 4 weeks of study treatment initiation.\n4. Major organ surgery (excluding puncture biopsy) or significant trauma within 4 weeks of study treatment initiation.\n5. Patients who received systemic treatment with either corticosteroids ( \\>10 mg\u002F daily prednisone or equivalent) or other immunosuppressive medications within 14 days of study treatment initiation.\n6. Subjects with any ≥Grade 1 toxicity (as per NCI CTC AE Version 5.0) related to prior anti-cancer therapy (except for toxicity that the investigator assessed to be no safety risk, such as alopecia.).\n7. Subjects with Central Nervous System (CNS) metastasis or meningeal metastasis .\n8. Seronegative for Herpes Simplex Virus (HSV) (HSV-1IgG and HSV-1IgM).\n9. Subjects with the relapse of HSV infection and relevant clinical manifestations, such as lip herpes, herpes keratitis, herpes dermatitis, and genital herpes.\n10. Subjects with other uncontrolled active infections.\n11. Known history of immunodeficiency and test positive of human immunodeficiency virus (HIV).\n12. History of severe cardiovascular disease:\n\n1)Ventricular arrhythmias requiring clinical intervention; 2)QTc interval \\>480 ms; 3)Acute coronary syndrome, congestive heart failure, stroke or other cardiovascular events of III grade or above within 6 months; 4)The cardiac function grade≥II or left ventricular ejection fraction (LVEF) \\<50% per the New York Heart Association (NYA); 5)Uncontrolled hypertension.\n\n13\\. Subjects with active or past autoimmune diseases that are likely to recur (e.g. systemic lupus erythematosus, rheumatoid arthritis, vasculitis, etc.); acceptable for patients with clinically stable autoimmune thyroiditis.\n\n14\\. Previous immunotherapy with an immune-related adverse event (irAE) such as immune-related pneumonia, myocarditis, etc., which, in the judgement of the investigator, may affect the safety of the investigational drug. 15. known to have alcohol or drug dependence. 16. Persons with mental disorders or poor compliance. 17. Pregnant or lactating women. 18. Subjects with any significant unrelated systemic illness that to the investigator's opinion would compromise the subject's eligibility to participate the study.",{"count":289,"type":21},44,[291],"PHASE1","VG161 is a recombinant human-IL12\u002F15\u002FPDL1B oncolytic HSV-1 Injectable. This phase I study will be conducted in HSV-seropositive subjects with advanced primary liver cancer that are refractory to conventional therapies. This is an open label study and it's divided into two parts.\n\nPart 1: This part is ascending dose design to determine the safety and tolerability of VG161 and find recommended dose of VG161.\n\nPart 2: This part is extended dose design to determine the effectiveness of VG161.",[31],[29],"2024-09-10",{"date":297,"type":61},"2024-09-19",{"date":299,"type":61},"2021-03-16",{"date":301,"type":21},"2024-12-31",{"name":303,"class":97},"CNBG-Virogin Biotech (Shanghai) Ltd.",{"id":305,"slug":306,"hasResults":11,"nctId":307,"briefTitle":308,"officialTitle":309,"acronym":310,"eligibilityCriteria":311,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":312,"targetDuration":314,"studyType":79,"phases":4,"briefSummary":315,"conditions":316,"keywords":321,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":323,"lastUpdatePostDateStruct":324,"startDateStruct":326,"completionDateStruct":328,"leadSponsor":330,"locationsCount":69},"100494126","liver-embolization-approaches-for-tumor-management-100494126","NCT05714124","Liver Embolization Approaches for Tumor Management","Liver Embolization Approaches for Tumor Management - Retrospective and Prospective Analysis of the Short-, Medium-, and Long-term Clinical Course of Patients Subjected to Embolization Treatment for Primary and Secondary Liver Neoplasms","LEATUM","Inclusion Criteria:\n\n* ≥ 18 yoa\n* patients with patients with primary or secondary liver disease not amenable for surgery or ablation\n* patients with primary or secondary liver tumors candidates for major surgery prior to induction of hypertrophy\n* able and willing to sign informed consent\n\nExclusion Criteria:\n\n* pregnant women\n* patients with uncorrectable coagulopathy\n* diffuse extrahepatic disease\n* for lobar TACE and TARE - presence of bilodigestive shunt\n* for TARE - \\>20% hepatopulmonary shunt",{"count":313,"type":21},580,"5 Years","The goal of this evaluate short, medium and long term outcome of the different embolization techniques in patients with primary and secondary hepatic tumors. The main aim is to evaluate progression free survival following embolization in this study population or evaluate residual hepatic volume in cases in which these techniques are used to induce liver regeneration. This study is an observational registry - all patients will follow their normal therapeutic and treatment scheme as per clinical practice, without any additional intervention.",[28,110,317,318,319,31,320],"Metastatic Colon Cancer","Metastatic Cancer","Metastatic Gastric Cancer","Metastatic Pancreatic Cancer",[322],"embolization, TAE, TACE, TARE, PVE, HVE","2024-04-11",{"date":325,"type":61},"2024-04-12",{"date":327,"type":61},"2021-05-21",{"date":329,"type":21},"2031-12-31",{"name":331,"class":68},"IRCCS San Raffaele"]